Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_1
5
71%
Ph phase_2
2
29%

Phase Distribution

5

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
5(71.4%)
Phase 2Efficacy & side effects
2(28.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (71.4%)
Phase 22 (28.6%)

Trials by Status

completed457%
terminated229%
withdrawn114%

Recent Activity

0 active trials
Showing 5 of 7
terminatedphase_1

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

NCT03742349
completedphase_1

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

NCT03455764
completedphase_1

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

NCT02807844
completedphase_2

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

NCT02435680
completedphase_2

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

NCT01643850
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03742349Phase 1

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Terminated
NCT03455764Phase 1

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Completed
NCT02807844Phase 1

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Completed
NCT02435680Phase 2

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Completed
NCT01643850Phase 2

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Completed
NCT00757757Phase 1

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Terminated
NCT03285607Phase 1

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Withdrawn

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7